The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy
Open accessAbstract
A randomized, double-blind trial comparing oral fluconazole (400 mg daily) with placebo as prophylaxis for adult patients receiving intensive cytotoxic therapy for acute leukemia or autologous bone marrow transplantation was conducted in 14 Canadian university-affiliated hospitals. Although fluconazole prophylaxis did not obviate the need for parenteral antifungal therapy compared with placebo (81 [57%] of 141 vs. 67 [50%] of 133, respectively), its use resulted in fewer superficial fungal infections (10 [7%] of 141 vs. 23 [18%] of 131, respectively; P = .02) and fewer definite and probable invasive fungal infections (9 vs. 32, respectively; P = .0001). Fluconazole recipients had fewer deaths attributable to definite invasive fungal infection (1 of 15 vs. 6 of 15, respectively; P = .04) and achieved more frequent success without fungal colonization (52 [37%] of 141 vs. 27 [20%] of 133, respectively; P = .004; relative risk reduction, 85%) than did placebo recipients. Patients benefiting the most from fluconazole prophylaxis included those with acute myeloid leukemia who were undergoing induction therapy with cytarabine plus anthracycline-based regimens and those receiving marrow autografts not supported with hematopoietic growth factors. Fluconazole prophylaxis reduces the incidence of superficial fungal infection and invasive fungal infection and fungal infection-related mortality among patients who are receiving intensive cytotoxic chemotherapy for remission induction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Self-citation2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Self-citationGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Waselenko, J. K., MacVittie, T. J., Blakely, W. F., Pesik, N., Wiley, A. L., Dickerson, W. E., Tsu, H., Confer, D. L., Coleman, C. N., Seed, T., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-12-200406150-00015 · Cited by 766
van Burik, J.-A. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J. W., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 744
Metadata
- Authors
- Rotstein, C., Bow, E. J., Laverdiere, M., Ioannou, S., Carr, D., Moghaddam, N., & The Canadian Fluconazole Prophylaxis Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-02
- Volume
- 28
- Issue
- 2
- Pages
- 331-340
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2109088397
- Cited by
- 265
- References
- 2
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy. https://app.cochat.ai/papers/10.1086/515128
- The paper
- Rotstein, C., Bow, E. J., Laverdiere, M., Ioannou, S., Carr, D., Moghaddam, N., & The Canadian Fluconazole Prophylaxis Study Group. (1999). Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy. Clinical Infectious Diseases. https://doi.org/10.1086/515128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.